Tagged Articles

urinary tract infections 26 articles

Top 5 most dangerous Invokana side effects

The type 2 diabetes drug Invokana hit the market in 2013 with much hype. It was the first drug in a new class of diabetes treatments known as SGLT2 inhibitors. Johnson & Johnson and its unit Janssen Pharmaceuticals, stood to make millions – if not billions – from its novel new diabetes pill. Unlike other diabetes drugs that work through the pancreas or liver, SGLT2 inhibitors are metabolized through the kidneys and lower blood sugar levels by excreting excess sugar through the urine. Invokana, which contains the drug ingredient canagliflozin, proved to be a huge hit and remains a top seller ... Read More

Invokana timeline reveals growing list of warnings

In March 2013, the Food and Drug Administration (FDA) approved a novel new type 2 diabetes treatment called Invokana. The drug, manufactured by Johnson & Johnson’s Janssen Pharmaceuticals, was the first in a class of diabetes drugs known as SGLT2 inhibitors. Unlike other diabetes medications that work through the pancreas or liver, Invokana lowers blood sugar by pushing excess sugar through the kidneys where it is excreted through the urine. The drug was almost an immediate hit, offering the benefit of weight loss to a population of patients often plagued by obesity. Other drugs, such as the Invokana and insulin ... Read More

Diabetics taking SGLT2 should be aware of urinary tract infection symptoms

At least 10 percent of diabetic patients treated with SGLT2 inhibitors will develop a genital fungal infection or lower urinary tract infection, and nearly 20 percent of them will have recurrent infections, researchers reported during a presentation at the American Academy of Physician Assistants. Thus, they urged, it is imperative that doctors treating patients with  these drugs tell them to be aware of the symptoms of these side effects. “You must speak to your patients prescribed sodium glucose co-transporter type 2 (SGLT2) inhibitors about mycotic infection because about 10 percent to 11 percent of your patient population is going to get a ... Read More

New diabetes drug tested as an add-on in triple therapy

Merck and Pfizer are teaming up on a new type 2 diabetes treatment and if clinical trials continue to show promise, they hope to apply for Food and Drug Administration (FDA) approval by the end of the year. The experimental drug, ertugliflozin is in a class of type 2 diabetes drugs called sodium glucose cotransporter 2 (SGLT2) inhibitors, which also includes the brand names Invokana, Invokamet and Jardiance. SGLT2 inhibitors work to lower blood sugar levels by blocking the reabsorption of glucose in the kidneys, allowing more sugar to be excreted through the urine. Ertugliflozin improved glycemic control in type ... Read More

NICE recommends diabetes drugs despite serious risks

The National Institute for Health and Care Excellence (NICE) is recommending the use of one of three drugs in a newer class of type 2 diabetes treatments if standard treatment is not suitable. The news comes on the heels of an announcement by the European drug regulator that it was conducting a safety review of one of the medications due to an increased risk of lower limb amputations and new warnings by the U.S. drug regulator for an increased risk of a serious condition called ketoacidosis. NICE is part of the UK’s Department of Health serving both the English National ... Read More

Elderly patients more vulnerable to Invokana side effects

A pooled analysis of adverse event reports in patients taking the type 2 diabetes medication Invokana found that patients 75 years and older were more likely to suffer Invokana side effects compared to patients younger than 75 treated with the drug. The study, published in The Journal of the American Geriatrics Society, was designed to compare the efficacy and safety of Invokana in younger patients versus elderly patients. Researchers measured HbA1c, fasting blood glucose, blood pressure and body weight for participants. Efficacy was evaluated using pooled data from six randomized, double-blind, placebo-controlled studies. Safety was assessed based on adverse event ... Read More

Invokana plagued by new side effects since its FDA approval

It’s been three years since the Food and Drug Administration (FDA) approved Johnson & Johnson’s Janssen Pharmaceutical’s drug Invokana (canagliflozin) as a treatment for type 2 diabetes. Since then, the FDA and other drug regulators have issued numerous warnings over new Invokana side effects that have emerged outside initial clinical trials. Invokana was the first drug approved in the United States in a class known as sodium glucose cotransporter 2 (SGLT2) inhibitors. Prescriptions for the drug have since soared, generating hundreds of millions in revenue. In May 2015, the FDA issued a Safety Communication warning that Invokana and two other ... Read More

Invokana warnings updated to include ketoacidosis risk

The safety label of the type 2 diabetes drug Invokana (canagliflozin) and others in its class have been updated to include a new warning for ketoacidosis, a serious life-threatening condition in which too much acid builds up in the blood causing complications such as difficulty breathing, nausea and vomiting, abdominal pain, confusion, unusual fatigue, diabetic coma and death. Invokana was approved by the Food and Drug Administration (FDA) in March 2013, becoming the first SGLT2 inhibitor to hit the market. It is manufactured by Johnson & Johnson subsidiary Janssen Pharmaceuticals. In May, the FDA ordered makers of SGLT2 inhibitors to ... Read More

Physicians group informs docs of new warnings on type 2 diabetes drug Invokana

AAFP News, the official news publication of the American Academy of Family Physicians, notified its membership of new warnings added to the labels of certain type 2 diabetes drugs. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as the brand name drugs Invokana and Invokamet, have been linked to serious urinary tract infections (UTIs) and ketoacidosis, a serious condition in which too much acid builds up in the blood. The Food and Drug Administration (FDA) conducted a safety review on the drugs after receiving a high number of reports of both conditions in patients taking SGLT2 inhibitors. The agency advised physicians to assess patients taking ... Read More

Man sues Invokana makers over serious blood disorder

Johnson & Johnson subsidiary Janssen Pharmaceuticals is being sued by a Texas man who claims the company’s type 2 diabetes drug Invokana caused him to develop ketoacidosis, a potentially life-threatening condition in which too much acid builds up in the blood. Arthur Portnoff, who filed his lawsuit in Philadelphia Court of Common Pleas, claims he began taking the drug in November 2014 and was hospitalized in February 2015 with ketoacidosis. He claims that Janssen knew the drug could cause serious injuries but failed to adequately warn patients or doctors of this risk. His complaint also states that Janssen did not ... Read More